Targets › GPCS
2 programs from 2 companies in 4 trials: 4 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on GPCS, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| CARsgen Therapeutics | CT011 CAR-GPC3 T Cells Injection Anti-GPC3 CAR-T cell therapy | GPCS | Phase 1 | HCC | Dec 2026 |
| Baylor College of Medicine | CARE T cells (15.21.GPC3-CAR T cells) Glypican-3-specific CAR T cells expressing interleukin-15 and interleukin-21 | GPC3, GPCS | Phase 1 | Liver Cancer; Hepatoblastoma; Glioblastoma Multiforme of Brain | Aug 2027 |
Liver Cancer (1) Hepatoblastoma (1) Glioblastoma Multiforme of Brain (1) HCC (1)
other (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.